EMA started the evaluation of Richter’s marketing authorisation application for biosimilar pegfilgrastim

Gedeon Richter Plc. (“Richter”) today announced that the European Medicines Agency (EMA) has accepted Richter’s regulatory submission for its proposed biosimilar to Amgen’s Neulasta (pegfilgrastim).